These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15355886)

  • 1. Detection characteristics in randomized prostate screening.
    Schröder FH; Roobol MJ
    Clin Cancer Res; 2004 Sep; 10(17):5641-2. PubMed ID: 15355886
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer screening. Why the controversy?
    Walther PJ
    Surg Oncol Clin N Am; 1995 Apr; 4(2):315-34. PubMed ID: 7540938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.
    Mian BM
    Urol Oncol; 2010; 28(3):233-6. PubMed ID: 20097584
    [No Abstract]   [Full Text] [Related]  

  • 4. PSA screening--a review of recent studies.
    Schröder FH
    Eur J Cancer; 2009 Sep; 45 Suppl 1():402-4. PubMed ID: 19775647
    [No Abstract]   [Full Text] [Related]  

  • 5. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prostate cancer screening].
    Saksela E
    Duodecim; 1997; 113(9):871. PubMed ID: 11466912
    [No Abstract]   [Full Text] [Related]  

  • 8. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
    Schröder FH; Roobol MJ
    BJU Int; 2009 Jan; 103(2):143-4. PubMed ID: 19076150
    [No Abstract]   [Full Text] [Related]  

  • 10. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemoprevention of prostate cancer: breakthroughs and controversies.
    Kim J
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1517-22. PubMed ID: 20942621
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer screening: is it possible to explain diametrically opposed views?
    Richardson A
    N Z Med J; 2005 Feb; 118(1209):U1289. PubMed ID: 15711622
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening.
    Med Lett Drugs Ther; 2008 Nov; 50(1298):85-6. PubMed ID: 18978703
    [No Abstract]   [Full Text] [Related]  

  • 15. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
    Richard F
    Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 17. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
    Loeb S; Carter HB
    Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnosis and treatment of prostate cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate.
    Loeb S; Catalona WJ
    Med Econ; 2008 Dec; 85(24):36-41. PubMed ID: 19209648
    [No Abstract]   [Full Text] [Related]  

  • 19. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Gosselaar C; Roobol MJ; Schröder FH
    BJU Int; 2005 Feb; 95(2):231-7. PubMed ID: 15667646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.